Duopharma earnings set to improve this year

TA Research said it remains optimistic on Duopharma’s growth prospects.

PETALING JAYA: Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.

In a report, TA Research said it remains optimistic on Duopharma’s growth prospects with catalysts coming from these two factors.